2022 - Research.com Chemistry in Switzerland Leader Award
Paul J. Dyson mainly focuses on Ruthenium, Ionic liquid, Stereochemistry, Organic chemistry and Catalysis. His Ruthenium research incorporates themes from Adduct, In vitro, Bioorganometallic chemistry and DNA. His studies deal with areas such as Inorganic chemistry, Polymer chemistry, Ion, Ionic bonding and Solubility as well as Ionic liquid.
The concepts of his Stereochemistry study are interwoven with issues in Medicinal chemistry, Ligand, Molecule, Cytotoxicity and Hexamethylbenzene. His research on Organic chemistry frequently links to adjacent areas such as Combinatorial chemistry. His Catalysis study incorporates themes from Carbon source and Nanoparticle.
Paul J. Dyson focuses on Ruthenium, Stereochemistry, Catalysis, Ionic liquid and Organic chemistry. Within one scientific family, Paul J. Dyson focuses on topics pertaining to Medicinal chemistry under Ruthenium, and may sometimes address concerns connected to Reactivity. The various areas that Paul J. Dyson examines in his Stereochemistry study include Molecule, Bioorganometallic chemistry, Crystal structure and Cytotoxicity.
He regularly links together related areas like Crystallography in his Molecule studies. His Catalysis research is multidisciplinary, incorporating perspectives in Nanoparticle and Chemical engineering. The Ionic liquid study combines topics in areas such as Solvent, Inorganic chemistry, Polymer chemistry and Ion, Ionic bonding.
Paul J. Dyson spends much of his time researching Catalysis, Chemical engineering, Ruthenium, Cytotoxicity and Ionic liquid. His Catalysis research is multidisciplinary, incorporating elements of Inorganic chemistry and Combinatorial chemistry. His study looks at the relationship between Chemical engineering and topics such as Polymer, which overlap with Ionic bonding, Nanoparticle and Membrane.
His Ruthenium research integrates issues from In vitro, Molecule and Metal. He combines subjects such as Cisplatin, Characterization, Rhodium, Ligand and Stereochemistry with his study of Cytotoxicity. His work investigates the relationship between Ionic liquid and topics such as Electrochemical reduction of carbon dioxide that intersect with problems in Electrochemistry.
Paul J. Dyson mostly deals with Catalysis, Ruthenium, Cytotoxicity, Perovskite and Ligand. His Catalysis study is concerned with Organic chemistry in general. His biological study spans a wide range of topics, including Ionic bonding and MTT assay.
His Cytotoxicity study which covers Stereochemistry that intersects with Molecule, Selectivity and Cisplatin. His study focuses on the intersection of Perovskite and fields such as Solar cell with connections in the field of Formamidinium, Inorganic chemistry, Dopant and Energy conversion efficiency. His research integrates issues of Prodrug, Cationic polymerization and Cell growth in his study of Ligand.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
Christian G. Hartinger;Christian G. Hartinger;Paul J. Dyson.
Chemical Society Reviews (2009)
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Claudine Scolaro;Alberta Bergamo;Laura Brescacin;Riccarda Delfino.
Journal of Medicinal Chemistry (2005)
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Christian G. Hartinger;Christian G. Hartinger;Michael A. Jakupec;Stefanie Zorbas‐Seifried;Michael Groessl.
Chemistry & Biodiversity (2008)
Efficient dehydrogenation of formic acid using an iron catalyst.
Albert Boddien;Dörthe Mellmann;Felix Gärtner;Ralf Jackstell.
Ruthenium in Medicine: Current Clinical Uses and Future Prospects
Claire Samantha Allardyce;Paul Joseph Dyson.
Platinum Metals Reviews (2001)
Why are ionic liquids liquid? A simple explanation based on lattice and solvation energies
Ingo Krossing;John M. Slattery;Corinne Daguenet;Paul J. Dyson.
Journal of the American Chemical Society (2006)
Metal-based antitumour drugs in the post genomic era.
Paul J. Dyson;Gianni Sava.
Dalton Transactions (2006)
[Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [18.104.22.168]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells
Claire S. Allardyce;Paul J. Dyson;David J. Ellis;Sarah L. Heath.
Chemical Communications (2001)
Selective degradation of wood lignin over noble-metal catalysts in a two-step process.
Ning Yan;Ning Yan;Chen Zhao;Paul J. Dyson;Chen Wang.
Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy
Wee Han Ang;Paul J. Dyson.
European Journal of Inorganic Chemistry (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: